Oncimmune announce IPO on AIM

Geoffrey Hamilton-Fairley, CEO of Oncimmune 

We are delighted that Oncimmune have today announced their IPO. The company have developed and patented a technology that detects cancer in its early stages, when the possibility of a cure is highest.

Balderton led a £5.25m round into Oncimmune in 2007, with Tim Bunting joining the board.

Congratulations to Geoffrey Hamilton-Fairley and the Oncimmune team, we look forward to their journey as a public company.

You can watch Geoffrey's interview with CNBC here

Stay in touch with Balderton

Sign up for our newsletter to stay up to date on news from Balderton, and our portfolio.